Background: Ventilator-associated pneumonia (VAP) is one of the most common health care-associated infections (HAIs) in critical care settings.
Objective: Our objective was to examine the effect of a series of interventions, implemented in 3 different periods to reduce the incidence of VAP in an intensive care unit (ICU).
Methods: A quasiexperimental study was conducted in a medical-surgical ICU. Multiple interventions to optimize VAP prevention were performed during different phases. From March 2001 to December 2002 (phase 1: P1), some Centers for Disease Control and Prevention (CDC) evidence-based practices were implemented. From January 2003 to December 2006 (P2), we intervened in these processes at the same time that performance monitoring was occurring at the bedside, and, from January 2007 to September 2008 (P3), we continued P2 interventions and implemented the Institute for Healthcare Improvement's ventilator bundle plus oral decontamination with chlorhexidine and continuous aspiration of subglottic secretions.
Results: The incidence density of VAP in the ICU per 1000 patient-days was 16.4 in phase 1, 15.0 in phase 2, and 10.4 in phase 3, P=.05. Getting to zero VAP was possible only in P3 when compliance with all interventions exceeded 95%.
Conclusion: These results suggest that reducing VAP rates to zero is a complex process that involves multiple performance measures and interventions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ajic.2009.03.009 | DOI Listing |
Syst Rev
January 2025
Department of Neurosurgery, Pingxiang People's Hospital, Pingxiang, Jiangxi Province, 337000, China.
Background: A systematic appraisal of the comparative efficacy and safety profiles of naso-intestinal tube versus gastric tube feeding in the context of enteral nutrition for mechanically ventilated (MV) patients is imperative. Such an evaluation is essential to inform clinical practice, ensuring that the chosen method of nutritional support is both optimal and safe for this patient population.
Methods: We executed an exhaustive search across PubMed et al.
Infect Prev Pract
March 2025
Cardio Thoracic and Vascular Surgery, PGIMER, Chandigarh, India.
Background: Infection prevention and control (IPC) practices by critical care nurses are crucial in preventing ventilator-associated pneumonia (VAP) and central-line-associated bloodstream infection (CLABSI).
Aim: To implement an integrative approach to developing a set of IPC practices and disseminating information on the IPC practices through an educational multimedia tool to improve compliance with the practices.
Methods: This participatory interventional before-after study was conducted in a single tertiary care centre's cardiac surgical intensive care unit (ICU) from May 2022 to March 2023.
Chest
January 2025
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. Electronic address:
Background: Ventilator-associated pneumonia (VAP) rates are higher in low- and middle-income countries (LMICs) than in high-income countries (HICs).
Research Question: Could differences in ventilator bundle adherence, ventilation practices, and critical care staffing be driving variations in VAP risk between LMICs and HICs?
Study Design And Methods: This secondary analysis of the multicenter, international CERTAIN study included mechanically ventilated patients at risk for VAP from eleven LMICs and five HICs. We included oral care, head-of-bed elevation, spontaneous breathing assessments, and sedation breaks in the ventilator bundle.
Crit Care Med
January 2025
Department of Surgery, University of Southern California, Los Angeles, CA.
Objectives: To explore practice variations in the rate and timing of tracheostomy and gastrostomy for adolescent with severe traumatic brain injury (TBI) across trauma center types.
Design: Retrospective cohort study.
Setting: Trauma centers participating in the American College of Surgeons Trauma Quality Improvement Program (2017-2021) included adult (ATC), mixed (MTC), and pediatric trauma centers (PTC).
Antimicrob Agents Chemother
January 2025
JMI Laboratories, Element Materials Technology, North Liberty, Iowa, USA.
Ceftobiprole was recently approved by the United States (US) Food and Drug Administration (FDA) for the treatment of adult patients with bacteremia, including right-side endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia in adults and pediatrics. Ceftobiprole is an advanced-generation cephalosporin approved in many countries for the treatment of adults with community-acquired pneumonia and hospital-acquired pneumonia, excluding ventilator-associated pneumonia. We evaluated the activities of ceftobiprole and comparators against methicillin-resistant (MRSA) and multidrug-resistant (MDR) clinical isolates.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!